What You Should Know:
Quest Diagnostics has reached an agreement to acquire Haystack Oncology an early-stage oncology company focused on minimal residual disease (MRD) testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisionsUnder the terms of the agreement, Quest will pay $300 million in cash at closing, net of cash acquired, and up to an additional $150 million on achieving future performance
Read More
dna
How AI is Transforming Rare Disease Diagnosis
Collectively rare diseases are anything but rare – they impact 30 million people in the US and ten times that amount globally. And 1 in 3 children suffering from a rare disease will not survive beyond the age of five.
One of the biggest challenges facing clinicians is making a quick, accurate diagnosis – on average patients visit eight physicians and receive two to three misdiagnoses before being correctly diagnosed, a process that takes US patients around 7.6 years, and is often referred to
Read More
COTA and GTC Partner to Improve Precision Oncology
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company, today announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company.
- GTC has a very innovative approach to genetic testing, providing molecular information which is critical to determining accurate diagnoses and determining the most appropriate treatment. GTC's tissue and liquid-biopsy testing leverages DNA and RNA sequencing, which is very rare in the
Read More
What Impact Could AI Have On Genetic Testing?
The sequencing and analysis of human DNA have advanced significantly since the initial draft of a human genome that was published as part of the Human Genome Project. With DNA sequencing becoming increasingly cost-effective, the market for genetic testing is growing at an accelerating rate – the market for Next Generation Sequencing (NGS) services has an estimated annual growth of 18.3% from 2022 to 2030. AI presents a range of possibilities for this rapidly growing field, and in this article,
Read More
Tempus Forms Multi-omics Collaboration With Actuate Therapeutics
What You Should Know:
- Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone.
- This multi-omics approach is being used by Actuate Therapeutics in support
Read More
It’s Time to Stop Accepting the Payer-Provider Dynamic as ‘Adversarial’ and Work Toward Alignment
Today’s relationship between payers and providers is more fraught than ever. With a history of transactional, often adversarial, fee-for-service contract negotiations, it’s no wonder that the healthcare industry has grown too comfortable pitting payers and providers against each other.
The lack of trust and transparency between the two groups has led to a perceived misalignment of vision. Across the board, the administrative staff has shouldered the brunt of this friction, which in the end
Read More
COVID-19 Health Systems Impact: What Will Stop The Cash Hemorrhage?
The material cost of COVID-19 has been at the center of public discourse since the early days of the pandemic. In 2020, growth in federal government spending on healthcare increased 36 percent, compared to the 5.9 percent bump in 2019. While the distribution of vaccines has allowed for a version of pre-pandemic life to resume, hospitals are still not recovered from the high rates of hospitalizations that occurred in March 2020, and the indirect costs of the pandemic continue to loom over the
Read More
Digital Health Funding Reaches $15.3B in 2022 Across 572 Deals, Rock Health Reports
What You Should Know:
- In a downtrodden market climate, things don’t need to feel doom and gloom, according to Rock Health’s Annual 2022 digital health funding report. 2022 was a necessary reminder that investment is cyclical and that strong players build resilience in weathering funding climate changes.
- Analysts expect that 2023 will be built up on slow, steady, and maybe even boring strategies for healthcare startups and enterprises alike: managing cash, restructuring to accommodate
Read More
C2i Genomics & AstraZeneca Partner to Advance Cancer Therapy
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a strategic collaboration with AstraZeneca, a global life sciences and pharmaceutical leader.
- The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers.
- Expanding on a completion of AstraZeneca’s accelerator BeyondBio SCALE program for start-ups and successful technology validation, C2i Genomics and AstraZeneca
Read More
WellSpan Health & Helix to Create Population Genomics Program
What You Should Know:
- WellSpan Health and Helix, the nation’s leading population genomics and viral surveillance company, announced today a partnership to create a comprehensive population genomics program designed to improve patient healthcare outcomes by integrating genetic insights into clinical care and research.
- Patients who are interested can have a DNA sample collected to generate genomic data. Once obtained, with their consent, the results from their sample will be integrated
Read More
